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Abstract
Prevalence of hepatitis C in HIV infected patients is much higher than in the 
general population. There is the possibility of viral clearance HCV, in some patients 
co-infected HIV and HCV, in the phase of immune reconstruction after antiretro-
viral treatment (ART). There are patients’ anti-HCV positive who initially did not 
show HCV viral load detected and after the start of ART becomes HCV viral load 
detectable. There are studies that described that immune restoration with increase 
in CD4+ and CD8+ T cells, from ART, was important in control of HCV viremia. 
Has been proposed hypothesis that direct or indirect effect of ART on HCV rep-
lication play a role in spontaneous resolution of HCV infection. We evaluated the 
co-infected patients with HIV and HCV under combined antiretroviral treatment, 
containing PI boosted with ritonavir in terms of immunological and virologi-
cal status (for both infection) and also liver disease. Patients were evaluated for 
liver damage by non-invasive methods. We have shown that a small percentage of 
patients have severe liver damage. We demonstrated the negative role of HCV on 
immunological status and in liver fibrosis in co-infected patients. A high proportion 
of these HIV and HCV co-infected patients had no detectable viremia, higher than 
other studies published.
Keywords: protease inhibitors, HCV, HIV, co-infection, non invasive liver fibrosis 
test, seroclearence
1. Introduction
Approximate 1/3 of HIV infected patients are also infected with hepatitis C virus 
(HCV) due to shared routes of transmission.
The clinical implications of this crossroad are important and challenging issues 
regarding the evaluation and management of the co-infected patient.
Patients with HIV and HCV infection have higher risk for developing cirrhosis, 
hepatic decompensation, increased rates of end-stage liver diseases, hepatocellular 
carcinoma and shortened lifespan after hepatic decompensation.
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2. Virology
There are similarities by virological point of view for these two viruses: HIV 
and HCV. Although both HIV and HCV are single-stranded RNA viruses with 
worldwide distribution, that can result in chronic, subclinical infection, they differ 
with regard to several important characteristics. HCV is a flavivirus, which does not 
replicate through a DNA-intermediate, as retroviruses do. This allows the possibility 
of eradication of HCV. HIV viral production rates are approximate 1010 virions per 
day with half life less than 6 hours and this production is even greater for HCV with 
production of 1012 virions per day and average virirons half-life 27 hours [1]. Details 
of the HCV replicative process are still not well known.
In chronic mono-infection with hepatitis C virus or HIV is maintained a viral 
load relatively stable as a “set point” over long periods of time. Virus specific T-cell 
responses play a role in the control of virus during chronic HCV.
In co-infection HIV and HCV, HCV RNA levels increase after HIV seroconver-
sion, and continue to increase over time, different from HCV mono-infection. 
Quantitative loss of memory lymphocytes that occurs in HIV infection could 
potentially be responsible for the elevated HCV RNA levels, observed in co-infected 
patients [2]. In combined infection, HCV viral load is related with level of immu-
nosuppression (inversely correlated with CD4 counts), and can increase with heavy 
alcohol use and transient with the antiretroviral therapy initiation [3]. HIV by 
himself can increase HCV replication due to gp120 protein (HIV envelope protein) 
through engagement of cellular co-receptors of HIV (ie, CXCR4 or CCR5) [4].
In addition to quantitative changes of T-cells, HIV may induce qualitative 
defects in immune responses through alteration of cytokine secretion profiles, and/
or dendritic cell function. Innate effectors, such as natural killer (NK) cells and 
natural killer T (NKT) cells, also mediate antiviral defenses. Disruption of NK cell 
function such as increased activation or decreased cytokine secretion induced by 
HIV-1 could also be responsible for the development of chronic HCV [5, 6].
HIV replicates in CD4+ T-cells as well in many cell types. There are controversial 
data regarding HCV replicates in extrahepatic sites, a study suggests peripheral blood 
mononuclear cells (PBMCs) [7]. Some studies have suggested that HCV RNA replica-
tion in PBMCs may occur in patients with HIV/HCV co-infection, but not in those 
with HCV alone [8]. The mechanism for the relapse of HCV viral load after HIV 
treatment discontinuation can be HCV replication in dendritic cells or PBMCs [9].
The higher rates of perinatal HCV transmission in co-infected patients can be 
explained by the fact that HCV has been isolated from the cervico-vaginal lavage 
fluid in HIV HCV positive women (not in HCV positive alone) [10].
After introduction of directly acting agents against HCV (DAA) it was demon-
strated the potential drug resistance for HCV parallels as in HIV, resistance muta-
tion to specific polymerase and protease HCV inhibitors [11].
3. Epidemiology
Since both infections have similar routes of transmission, co-infection HIV and 
HCV is common. The prevalence of co-infection varies by geographic areas, across 
risk groups, by route of transmission. Also the sequence of infection depends by 
transmission route.
HCV infection is transmitted by percutaneous route with highest rates in 
people who inject drugs (PWID) and hemophiliacs. The risk of post-transfusion 
HCV infection deeply decreases. Injection drug use is the most important route of 
HCV transmission, approximately 80% of HIV persons with history of injection 
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drug use are infected with HCV, and they usually acquire HCV before HIV infection 
while men who have sex with men (MSM) typically are infected with HIV before 
HCV infection [12].
HIV is much easily transmissible via sexual intercourse than HCV. In hetero-
sexual partners the prevalence of HCV co-infection is estimated as 4% in persons 
whose main HIV exposure risk is heterosexual sex with multiple partners. Globally, 
is estimated a 6.4% of HCV/HIV co-infection prevalence among MSM, with varia-
tions depending on the geographic region [13]. In MSM, HCV acquisition is associ-
ated with unprotected anal intercourse, group sex, fisting and recreational drugs 
[14]. HCV transmission may be increased by mucosal injury and/or concomitant 
other sexually transmitted diseases [15]. Ongoing HCV transmission is occurring in 
MSM with declining after DAAs but high rate of reinfection.
Regarding perinatal transmission of HCV, vertical transmission of HCV seems 
to be facilitated by HIV co-infection. Maternal co-infection increases the risk 
of vertical HCV transmission to their infants with about 2.82 fold more than for 
women who are infected with HCV alone [16].
There are rare reported cases of acquisition HIV and HCV via percutaneous 
exposure in health care workers.
4. Pathophysiology
Patients with co-infection HIV/HCV have higher rates of liver fibrosis progres-
sion compared with patients with HCV alone.
In patients with HIV, liver fibrosis progression is linked to week cellular immune 
responses to HCV antigens. The cellular immune response to viral infection is 
linked to CD8+ T-cell responses and in HIV infection there is a decreases number of 
CD4 cells, functional impairment of CD4 and CD8 cells and a down-regulation of a 
co-stimulatory molecule necessary for lymphocyte activation CD28. These observa-
tions explain the link between liver progression and advanced immunosuppression.
Also, liver progression can be determined by chronic immune activation through 
increased levels of pro-inflammatory cytokines, secondary to HIV infection. 
Kupffer cell depletion is associated with CD4 cell decline and may be related to 
development of fibrosis [17].
In HCV related liver fibrosis, activated hepatic stellate cells (HSCs) mediate 
collagen formation. There levels were associated with T cell immune activation 
and increased gene expression of interleukin-15. In HIV/HCV patients IL-15 play a 
pathogenic role in mediating liver fibrosis [18].
In normal hepatocytes apoptosis is mediated by tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL). Glycoproteins of HIV (gp120) through upreg-
ulation of TRAIL-mediated apoptosis triggered to hepatocytes death [19].
HCV-associated proinflammatory cytokines may contribute to liver fibrosis 
progression and these may have a damaging effect on HIV disease [18].
In acute HCV infection, patients with HIV, especially those with low CD4 
counts, have lower rates of spontaneous virologic clearance.
In co-infected patients there is a much more rapid rate of progression to cir-
rhosis than in HCV alone [20]. The prevalence of extensive liver fibrosis was higher 
in coinfected patients [21]. Non-invasive assessments of liver fibrosis can be used 
more frequently and these also suggested more rapid fibrosis progression in coin-
fection but this can be related with the degree of HIV-immunosuppression.
In coinfection, as in monoinfection, some patients clinical characteristics: older 
age, diabetes, alcohol consumption, diabetes, obesity, elevated liver enzymes, have 
been associated with fibrosis progression [22].
Update on Hepatitis C
4
5. Effect of antiretroviral treatment (ART) on HCV progression
There are studies that suggested a decline in liver-related mortality associated 
with a potent ART introduction which also slows the rates of fibrosis progres-
sion, due to immune reconstruction [23]. A cross-sectional study demonstrated 
a lower necroinflammatory activity on liver biopsy in HIV viral suppressed ART 
patients and another study showed an increased risk of fibrosis progression in those 
patients with ART interruption [24, 25]. There is a decrease in AIDS and non-AIDS 
related morbidity and mortality in HIV patients with early ART initiation and this 
approach is important especially in HIV/HCV patients. There is evidence that use of 
ART partially restores T-cell responses to core HCV peptides. Successful response 
to ART among HIV/HCV patients is associated with increased cellular immune 
responses to HCV infection, long-term reduction in HCV RNA levels and with HCV 
clearance [26].
Drug induced liver injury (DILI) is more common in HIV/HCV coinfection 
following ART. Even liver toxicity is more common in patients with chronic viral 
hepatitis the benefit of ART exceeds the risk of liver injury. Some studies found an 
increased risk not for all ART regimens, only for some antiretroviral agents, such as 
ritonavir or nevirapine [27, 28].
The role of particular drug or antiretroviral class in liver progression rates is 
questionable, there are conflicting data. In a retrospective analysis, the authors 
observed that along with young age at infection, heavy alcohol use, and a low CD4 
count, patients whose ART regimen did not contain a protease inhibitor (PI) had 
higher inflammation and fibrosis scores when compared to those who took a PI 
as part of their ART regimen [29]. In another retrospective analysis of coinfected 
patients, no significant differences in the proportion of severe fibrosis (approxi-
mately 25%) were observed between those on an non-nucleoside reverse transcrip-
tase inhibitors (NNRTI), a PI, or both [30] Therefore, specific PI or NNRTI use may 
not be associated with evident histological benefit or obvious histological worsen-
ing of HCV disease.
There are conflicting studies regarding the role of HCV in clinical progression 
of HIV disease. Some studies have suggested that co-infected patients have an 
increased progression to AIDS, as well as a decrease in survival from the time of 
diagnosis of HIV and AIDS [31, 32].
6.  Treatment of chronic hepatitis C virus infection in the patient  
with HIV
The goal of HCV antiviral treatment is to cure the infection, characterized by 
achievement of a sustained virological response (SVR) defined as an undetectable 
HCV RNA at week 12 to 24 after the end of treatment. Thus, an effective cure is 
associated with substantial reduction in liver-related mortality and morbidity and 
reduced incidence of hepatocellular carcinoma.
HIV/HCV coinfected patients had lower response rates to HCV treatment with 
peginterferon and ribavirin regimens compared with individuals without HIV. They 
have comparable SVR rates with DAA-regimens as HCV-monoinfected patients. 
Eradication of HCV infection may reduce the antiretrovirus-associated DILI.
The decision of optimal regimen and timing vary based upon: genotype, the 
stage of liver disease, prior treatment history, drug interaction and some medical 
and social priorities.
Because of the more rapid progression of liver fibrosis in the settings of HIV 
infection, coinfected patients should be prioritized for HCV antiviral therapy and 
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another reason to prioritize HCV treatment is cirrhosis and bridging fibrosis. With 
highly effective interferon-free regimens (DAA), curative all-oral treatment is 
possible also for those patients with coinfection. There is a low incidence of adverse 
events and high efficacy and that means that almost all patients can benefit from 
HCV treatment.
All HIV patients should be evaluated for chronic HCV infection using a third 
generation enzyme immunoassay. Patients found to be HCV positive should 
undergo quantitative HCV RNA testing to confirm the presence of viremia. HIV 
patients who are found to be HCV seronegative but if they are with advanced 
immnuosuppression (CD4 counts<100 cells/mm3), risk factors for HCV acquisition 
or elevated liver enzymes should undergo HCV-RNA testing.
Evaluation for coinfected patients for HCV treatment, by the point of view of 
HCV infection, is similar to those monoinfected. Prior to treatment evaluation 
should focus on these factors: HCV genotype, viral resistance testing for certain 
populations, history of prior treatment, assessment of liver fibrosis stage using 
noninvasive tests for fibrosis or liver biopsy, history, physical and basic laboratory 
tests, evaluation for conditions that might affect the therapy.
6.1 Management of antiretroviral treatment in coinfected patients
Timing of HCV therapy in relation to ART initiation in ART-naïve patients is 
important and that it will be discussed below. For special population, such as those 
with decompensate liver diseases, the treatment should be established only in 
specialized center with expertise in managing HIV/HCV coinfection.
For HIV/HCV coinfected patients whom are considered to receive HCV treat-
ment, the appropriate antiretroviral treatment regimen used should not have serious 
drug interaction with HCV antiviral agents. Another management issue in coin-
fected patients is the timing of antiretroviral therapy initiation or regimen switch.  
It is not recommended an ART interruption to allow HCV antiviral therapy [33].
In ART-naive HIV/HCV patients is preferable to start ART first and begin HCV 
treatment later. HIV/HCV patients should be initiated on ART for HIV disease 
without taking into account their CD4 cell count [34]. In selection of ART regi-
men should be taken into account the potential drug–drug interactions with HCV 
antivirals. It is recommended to initiate ART approximately 4 to 6 weeks before 
starting HCV therapy for two reasons: initiation of ART first allows assessment of 
tolerability and adverse effects of ART alone and the second reasons is an improved 
HCV outcome, by suppression HIV viral load by ART treatment through restoration 
of immune response or other effects [35].
In ART-experienced HIV/HCV patients, who achieved HIV viral suppression on 
an ART well tolerate regimen, should continue the regimen, if it does not have sig-
nificant drug interactions with the HCV treatment selected. A regimen switch may 
be necessary if ART regimen components cannot be used with HCV antiviral drugs. 
In failure to suppress HIV or adverse effects or intolerance to an ART regimen, the 
regimen switch should be indicated. In this case should be taken into account in 
selection of a new ART regimen potential drug interaction with HCV-antivirals, in 
addition to all specific recommendations that appeared in the choice of ART regi-
men in treatment-experienced patients. In ART regimen switches, prior antiretro-
viral history drugs and resistance profiles should be studied, to ensure that the new 
regimen is active, with two or three fully active antiretroviral drugs. The treatment 
should be initiated after 4 to 6 weeks after ART regimen switch by the same reasons 
as in ART-naive patients. Additionally, HIV RNA should be determined at 4 to 
6 weeks after the switch to ensure that the new regimen maintains HIV viral sup-
pression. If it is wished to switch back, the new ART regimen to the original ART 
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regimen, following completion of HCV treatment, this should be delayed until at 
least two weeks after completion of HCV treatment, to ensure clearance of the HCV 
antivirals [34].
6.2 HCV regimen selection in coinfected patients
The efficacy of DAA regimens among HIV/HCV coinfected patients it seems to 
be comparable to that in HCV monoinfected patients, the regimen selection deci-
sions are similar for these two groups.
The HCV selection regimen is based on genotype, prior HCV treatment, the stage 
of liver fibrosis and in rare cases by the presence of baseline NS5A inhibitor resistance 
associated substitutions. In co-infected patients, the HCV regimen drug interaction 
with HIV antiretroviral is the major consideration in selection of HCV regimen.
The regimen options for coinfected patients with a particular genotype are the 
same as those for HCV monoinfected patients with the same genotype. Potential 
drug interactions with antiretroviral regimen is the major consideration factor that 
decide between the several regimens available for a specific genotype. There are 
regimens that have been studied in coinfected patients.
6.2.1 Genotype 1 HCV infection
• Elbasvir-grazoprevir- high efficacy of this regimen in HIV/HCV patients. 
Analysis in monoinfected patients has suggested an association between 
lower SVR rates and pre-existing variations in the genotype’s 1 NS5A inhibi-
tor sequence. In genotype-1a infected patients is recommended testing for 
these resistance-associated substitution, and, if present, adding ribavirin and 
extended to 16 weeks the duration of treatment [35, 36].
• Sofosbuvir- velpatasvir- is a highly effective pangenotypic regimen, for 
12 weeks, the SVR rates are high regardless cirrhosis or treatment history [37].
 ○ Sofosbuvir-velpatasvir-voxilaprevir, a regimen reserved for patients who 
failed on certain DAA-regimen, can be used also for 8 weeks in naïve 
patients, has not been studied in coinfected patients but is thought to be the 
same efficient as in monoinfected patients
• Glecaprevir-pibrentasvir, is also a potent effective pangenotypic regimen, with 
high efficiency in coinfected patients treatment for 8 or 12 weeks [38].
• Ledipasvir-sofosbuvir- is highly effective in several studies in coinfected 
patients treatment naive or experienced, for 12 weeks, with high SVR overall 
even in patients with cirrhosis or prior treatment failure [39].
• Ombitasvir- paritaprevir- ritonavir plus dasabuvir- this regimen with or 
without ribavirin is highly effective for coinfected patients with genotype1, 
given for 12 to 24 weeks (depending on the infection subtype and the presence 
of cirrhosis) [40].
• Simeprevir and sofosbuvir – effective in HIV/HCV patients with cirrhosis who 
had failed to a prior regimen, given 16 or 24 weeks. (telaprevir plus pegin-
terferon and ribavirin) [41]. The SVR rates in real-life are higher in patients 
without these negative predictors of response.
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• Daclatasvir combinations
 ○ Daclatasvir plus sofosbuvir is highly effective for genotype 1, 12 weeks of 
treatment in naïve or experienced- coinfected patients. For these regimens, 
allowed ART agents included darunavir, atazanavir, or lovinavir, each 
ritonavir-boosted, efavirenz, rilpivirine, raltegravir and dolutegravir. When 
it is used with specific asntiretrovirals, the dose adjustment of daclatasvir is 
needed.
 ○ Daclatasvir plus asunaprevir is available in Japan for genotype 1b infection.
6.2.2  Genotype 2 infection: highly effective options, formally evaluated for 
coinfected patients
• Sofosbuvir-velpatasvir 12 weeks [37].
• Glecaprevir-pibrentasvir 8 weeks in non-cirrothic patients, 12 weeks for 
patients with compensated cirrhosis.[38]. The choice between them depends 
on drug interaction.
• Sofosbuvir- velpatasvir-voxilaprevir – reserved for patients who previously 
failed on an certain DAA regimen, 8 weeks treatment, has not been studied for 
HIV/HCV patients
Administration and dosing of these regimens in coinfected patients are similar 
to monoinfection.
6.2.3 Genotype 3 infection
• Glecaprevir-pibrentasvir for 8 to 16 weeks depending on treatment history and 
presence of cirrhosis
• Sofosbuvir-velpatasvir with or without ribavirin for 12 weeks.
• Daclatasvir plus sofosbuvir
• Sofosbuvir- velpatasvir-voxilaprevir – reserved for patients who previously 
failed on an certain DAA regimen,, has not been studied for HIV/HCV patients
The choice between them depends on drug interaction. The studies are in a 
limited number of coinfected patients [37, 38].
6.2.4 Genotype 4, 5 and 6 infection
Studies in limited numbers of coinfected patients have demonstrated good effi-
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6.3 Potential drug interaction with ART
When assessing a HIV/HCV patient for HCV treatment there some important 
drug interactions to be considered.
• ribavirin. The interaction between it and antiretroviral agents include direct 
interaction but also a combination that potentiate adverse effects (with 
atazanavir- containing ART, patients may develop jaundice).
• sofosbuvir. Have few drug interactions with antiretroviral agents. In clinical 
studies was used in combination with tenofovir disoproxil fumarate- emtric-
itabine (TDF-EMT), efavirenz, darunavir or atazanavir boosted with ritonavir, 
raltegravir and rilpivirine, without any evidence of decreased efficacyor 
adverse events.
• ledipasvir- sofosbuvir. It is available only as a fixed-dose combination. 
Co-administration with tenofovir disoproxil fumarate (TDF), increased levels 
of tenofovir. Co-admistration with tenofovir alafenamide (TAF) does not 
elevate plasma levels of tenofovir, that’s why we can switch patients from TDF 
to TAF containing regimen when planning a treatment with ledipasvir- sofos-
buvir. There are specific options for different TDF-containing antiretrovirals in 
combination with ledipasvir-sofosbuvir.
• sofosbuvir –velpatasvir is only available in fixed-dose combination. There are 
no evidence of interaction or adverse events in combination with abacavir, ata-
zanavir, darunavir, ritonavir, cobicistat, elvitegravir, raltegravir, lamivudine, 
emtricitabine, TAF, rilpivirine.
• glecaprevir-pibrentasvir is available in fixed-dose combination. It was used in 
studies in combination with tenofovor, abacavirm, lamivudine, emtricitabine, 
raltegravir, dolutegravir, evitegravir with cobicistat and rilpivirine without 
clinical relevant interactions.
• elbasvir-grazoprevir- is available in fixed-dose combination. Both are primarly 
metabolized through CYP3A metabolism, thus, coadminsitration with several 
antiretrovirals is not advised. It can be used in combination with tenofovir, 
lamivudine, abacavir, emtricitabine, rilpivirine and dolutegravir, raltegravir.
• Ombitasvir-paritaprevir-ritonavir plus dasabuvir. Drug –interactions are 
expected since all of these agents are substrates and inhibitors of major 
metabolic enzymes. It was used safely with TDF-FTC and raltegravir, or in 
combination with atazanavir, when ritonavir boosting was served by ritonavir 
contained in HCV regimen.
• voxilaprevir, is available in fixed-dose combination pills with sofosbuvir and 
velpatasvir. Voxilaprevir is a substrate and inhibitor of P-glycoprotein, slowly 
metabolized by CYP34A. Coadministration with several antiretrovirals is not 
advised.
• daclatasvir is metabolized by CYP3A, thus inducers or inhibitors of these 
enzyme are expected to modify daclatasvir concentration.
• simeprevir is oxidatively metabolized by CYP3A. Inducers or inhibitors of 
CYP3A are expected to modify simeprevir concentration.
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Patients should be monitored for side effects and adherence, viral loads 
responses on therapy and also depending on ART regimen all the tests needed for 
evaluate side effects or toxicity.
7. Personal contribution
In our hospital, we are treating patients with HIV infection for about 20 years, 
with a history of long-term antiretroviral regimens which include protease inhibi-
tors (PI). The newly regimens for HCV treatment with direct-acting antivirals con-
tains protease inhibitors (PI) and ritonavir for HCV infection, like in HIV infection.
In our clinic there are 4.33% patients HIV/HCV coinfected, this incidence is 
similar to HCV in general population in Romania. In a previous study using nonin-
vasive methods FibroScan (transient elasthography) we demonstrated that 84.6% 
of HIV patients had mild or no fibrosis, 15.4% had moderate–severe fibrosis, and 
no cirrhosis [42]. We also demonstrated the concordance between noninvasive 
fibrosis evaluation methods Fibroscan, APRI and FIB-4 score for HIV [43, 44] and 
in literature these are used in coinfected HIV/HCV patients monitoring.
We evaluated the patients HIV/HCV coinfected under combined antiretroviral 
treatment containing PI boosted with ritonavir in terms of immunological and 
virological status (for both HIV and HCV infection) and also liver disease. Patients 
were evaluated for liver damage by non-invasive methods, APRI score and FIB-4.
By immunological HIV status 64.5% have CD4 ≥ 500cells/mm3, 29.03% have 
CD4 = 200-499cells/mm3, and 6.45% CD4 ≤ 200cells/mm3. HIV viral load was 
<40 copies/ml in 70% of cases, 11% presented less than 100 copies/ml, and 19% of 
patients, noncompliant to ART treatment, with detectable HIV viral load.
Using APRI score 69% of HIV/HCV patients have APRI < 0.5, representing mild 
or no fibrosis, 24% moderate or severe fibrosis and 7%, APRI > 1.5 corresponding 
to cirrhosis. The same results are when we used FIB-4 score: 77% no/mild fibrosis, 
(FIB4 < 1.45), 16% moderate/severe fibrosis, 7% cirrhosis (FIB-4 > 3.25. We have 
shown that a small percentage of patients have severe liver damage but significantly 
higher in HIV HCV co-infection than in mono HIV infected persons (Table 1).
In another study on these cohort 34% of coinfected patients have undetectable 
HCV viral load without any HCV regimen only the same exposure to PI, (ritonavir-
boosted lopinavir majority or other PI) [45]. This seroclearence can be explained by 
immune reconstruction induced by antiretroviral treatment or by direct antiviral 
effect of PIs on HCV infection.
A high proportion of these HIV/HCV co-infected patients had no detectable 
viremia, higher than other studies published which may be explained by the fact 
that these patients have had HCV clearance, spontaneous or induced by the antiret-
roviral therapy.
Infection Non-invasive liver 
fibrosis tests
Fibrosis
No/mild (%) Moderate/severe (%) Cirrhosis (%)
HIV APRI 84.6 15.4 0
FIB-4 82.0 18.0 0
HIV/HCV APRI 69 24 7
FIB-4 77 16 7
Table 1. 
Liver fibrosis.
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The immunological and virological HIV status of these undetectable HCV viral 
load patients was better than in those with detectabile HCV viral load. There are 
also diferencies regarding PI regimens and duration between these two groups. We 
have limited experience on DAA treatment in HIV/HCV coinfected patients.
8. Conclusion
With the growing availability and diversity of direct-acting antiviral combina-
tion regimen for HCV treatment, a curative treatment will be possible for majority 
patients, even those with HIV.
The sustained virologic response rates in coinfected patients treated with DAA 
are similar with monoinfected patients, with almost the same regimens. These are 
associated with substantial reductions in liver-related morbidity and mortality. A 
testing algorithm based on primary care screening (e.g. with APRI, FIB-4) followed 
by referral for specialty confirmatory testing (e.g, transient elastography) would 
best fit most practice models.
There are some management issues in HIV/HCV coinfection regarding appro-
priate antiretroviral regimens and drug interactions with HCV treatment.
With these DAA regimens, as in HIV preexposure prophylaxis (PrEP), maybe 
we can limit the extension of HCV infections in some risk group of HIV patients.
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